Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-12-09 Sale | 2024-12-10 4:53 pm | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 9,136 | $2.18 | $19,916 | 157,629 (Direct) | View |
| 2024-12-05 Sale | 2024-12-09 4:05 pm | Allogene Therapeutics Inc. | ALLO | Humer Franz B Director | 9,221 | $2.16 | $19,917 | 307,507 (Direct) | View |
| 2024-06-18 Sale | 2024-06-20 4:31 pm | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 18,641 | $2.2793 | $42,488 | 166,765 (Direct) | View |
| 2024-05-30 Sale | 2024-06-03 4:09 pm | Allogene Therapeutics Inc. | ALLO | Humer Franz B Director | 11,200 | $2.3376 | $26,181 | 255,253 (Direct) | View |
| 2024-05-16 Purchase | 2024-05-20 9:33 pm | Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director | 1,724,137 | $2.9 | $4,999,997 | 10,099,279 (Indirect Direct) | View |
| 2024-01-30 Purchase | 2024-03-06 9:52 pm | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 190 | $3.595 | $683 | 819,590 (Direct) | View |
| 2023-12-18 Sale | 2023-12-20 4:26 pm | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 18,640 | $2.6994 | $50,317 | 62,456 (Direct) | View |
| 2023-08-07 Sale | 2023-08-09 4:07 pm | Allogene Therapeutics Inc. | ALLO | Mayo Stephen Director | 10,000 | $4.2855 | $42,855 | 25,328 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-10-21 Tax Withholding | 2024-10-23 4:21 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 36,404 | $2.84 | 1,131,988 (Direct) | View |
| 2024-08-21 Tax Withholding | 2024-08-23 4:15 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel | 28,310 | $2.785 | 449,324 (Direct) | View |
Ownership | 2024-06-11 4:10 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Yoshiyama Annie SVP, Finance | 0 | $0 | 450,466 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:35 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | Mayo Stephen Director | 191,082 | $0 | 191,082 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:34 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | Barrett Elizabeth A. Director | 191,082 | $0 | 191,082 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:33 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director | 157,016 | $0 | 258,116 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:30 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | Humer Franz B Director | 157,016 | $0 | 412,269 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:29 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director | 191,082 | $0 | 191,082 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:28 pm | N/A 2034-06-05 | Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director | 191,082 | $0 | 191,082 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 5:25 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 122,950 | $0 | 185,406 (Direct) | View |
| 2024-05-16 Option Award | 2024-05-20 9:33 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director | 344,828 | $2.9 | 10,099,279 (Indirect) | View |
| 2024-05-16 Option Award | 2024-05-20 6:02 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 344,828 | $2.9 | 1,164,418 (Direct) | View |
| 2024-05-16 Option Award | 2024-05-20 6:01 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 344,828 | $2.9 | 7,723,302 (Direct) | View |
| 2024-04-22 Tax Withholding | 2024-04-24 4:18 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer | 17,360 | $3.4671 | 265,459 (Direct) | View |
| 2024-03-14 Tax Withholding | 2024-03-18 8:10 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 53,393 | $4.33 | 7,378,474 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:51 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer | 438,115 | $0 | 624,334 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:48 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel | 189,578 | $0 | 625,412 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:47 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 133,339 | $0 | 923,339 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:46 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director | 961,371 | $0 | 9,319,579 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:45 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 634,949 | $0 | 1,010,202 (Direct) | View |
| 2024-01-25 Option Award | 2024-01-31 5:42 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 1,441,335 | $0 | 8,549,934 (Direct) | View |
| 2024-01-22 Tax Withholding | 2024-01-24 5:25 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 24,690 | $3.1744 | 375,253 (Direct) | View |
| 2023-10-16 Option Award | 2023-10-17 5:02 pm | N/A 2033-10-16 | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 1,740,000 | $0 | 1,740,000 (Direct) | View |
| 2023-08-14 Option Award | 2023-08-17 6:57 pm | N/A 2033-08-14 | Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin GENERAL COUNSEL | 1,396,688 | $0 | 1,396,688 (Direct) | View |
| 2023-08-10 Option Award | 2023-08-14 7:59 pm | N/A 2033-08-10 | Allogene Therapeutics Inc. | ALLO | CHEN YINLIN JACK SVP, Finance | 50,561 | $0 | 128,041 (Direct) | View |
Ownership | 2023-08-14 7:28 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | CHEN YINLIN JACK SVP, Finance | 0 | $0 | 272,725 (Direct) | View |
| 2023-06-13 Option Award | 2023-06-15 5:06 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 74,561 | $0 | 81,096 (Direct) | View |
| 2023-06-13 Option Award | 2023-06-15 5:03 pm | N/A 2033-06-13 | Allogene Therapeutics Inc. | ALLO | Barrett Elizabeth A. Director | 116,120 | $0 | 116,120 (Direct) | View |
| 2023-06-13 Option Award | 2023-06-15 5:02 pm | N/A 2033-06-13 | Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director | 82,873 | $0 | 124,324 (Direct) | View |
| 2023-06-13 Option Award | 2023-06-15 5:01 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Humer Franz B Director | 74,561 | $0 | 266,453 (Direct) | View |
| 2023-06-13 Option Award | 2023-06-15 5:00 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director | 74,561 | $0 | 292,832 (Direct) | View |